EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR TherapyColon cancerEGFR proteinSidednessAnti-EGFR therapyRight- and left-sided colorectal cancers (RSCRC and LSCRC, respectively) are different developmentally, genetically and ...
While KRAS mutations are common in colorectal cancers, NRAS mutations are relatively rare and the coexistence of multiple RAS mutations is not documented, presumably reflecting similar functions of wild-type and mutant forms of RAS. Recent experimental evidence has suggested that KRAS and NRAS may in...
近日,《肿瘤学年鉴》(Annals Of Oncology)发表了题为:Different prognostic values ofKRASexon 2 submutations andBRAF V600Emutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDE...
◆Despite uncertainty over its role as a predictive marker, it is clear that mutations in BRAF are a strong prognostic marker. prospective analysis of tissues from patients with stage II and III colon cancer enrolled i...
Therefore, BI-2865 can inhibit many of the common KRAS mutations seen in cancer, including G12D, G12V, G12C, and G13D, as well as wild-type KRAS [176,177]. A phase 1 trial of BI-3706674, a similar compound to BI-2865 that inhibits multiple KRAS variants, is planned (NCT06056024...
Left - KRAS mutant patients, HR = 0.172, p-value < 0.001; right - KRAS wild-type patients, HR = 0.794, p-value = 0.357. Full size image We also assessed the relationship between UHRF1 expression and the expression of previously published lung cancer-specific tumor ...
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105ArticlePubMedGoogle ScholarCrossref 8. Heinemann...
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study ArticleOpen access23 August 2024 Main Systemic anticancer therapy based on the chemotherapeutic agents 5-fluorouracil (5-FU)/capecitabine, oxaliplatin...
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II ... Cetuximab-containing chemotherapy is known to be effective for KRAS wild-type metastatic colorectal cancer; however, it is not clear whether...
Approximately 30-50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene, indicating that up to 50% of patients with colorectal cancer (CRC) might respond to anti-epidermal growth factor receptor (EGFR) antibody therapy. However, 40-60% of patients with wild-type KRAS tumo...